NCT05440344

A Study of Imlunestrant (LY3484356) in Female Participants With Impaired Liver Function

Pharmacokinetics of Imlunestrant in Participants With Hepatic Impairment

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 27 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The main purpose of this study is to measure how much of Imlunestrant (LY3484356) gets into the bloodstream and how long it takes the body to eliminate it in female participants with impaired liver function compared to female participants with normal liver function. The side effects and tolerability of Imlunestrant will also be evaluated. The study may last up to 46 days for each participant.

Conditions

• Hepatic Insufficiency
• Healthy

Interventions

Type	Name	Description
DRUG	Imlunestrant	Administered orally.

Timeline

• Start date: 2022-07-05
• Primary completion: 2024-02-28
• Completion: 2024-02-28
• First posted: 2022-06-30
• Last updated: 2025-11-12
• Results posted: 2025-11-12

Locations

3 sites across 1 country: United States

Regulatory

• FDA-regulated drug study